Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma

Clinical Cancer Research

Volumn 14, Issue 24, 2008, Pages 8302-8307

  Solit, David B ^a   Osman, Iman ^a   Polsky, David ^a   Panageas, Katherine S ^a   Daud, Adil ^b   Goydos, James S ^c   Teitcher, Jerrold ^a   Wolchok, Jedd D ^a   Joseph Germino, F ^c   Krown, Susan E ^a   Coit, Daniel ^a   Rosen, Neal ^a   Chapman, Paul B ^a,d  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; CYCLIN D1; HEAT SHOCK PROTEIN 70; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; TANESPIMYCIN; 17-(ALLYLAMINO)-17-DEMETHOXYGELDANAMYCIN; BENZOQUINONE DERIVATIVE; BRAF PROTEIN, HUMAN; HEAT SHOCK PROTEIN 90; MACROCYCLIC LACTAM; UNCLASSIFIED DRUG;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIAPHORESIS; DNA SEQUENCE; EDEMA; FATIGUE; FEMALE; FEVER; GENE MUTATION; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MELANOMA; METASTASIS; MULTICENTER STUDY; MUSCULOSKELETAL PAIN; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIDE EFFECT; TREATMENT RESPONSE; TUMOR BIOPSY; URINARY FREQUENCY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; MIDDLE AGED; MUTATION; SIGNAL TRANSDUCTION;

ADULT; AGED; BENZOQUINONES; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; MALE; MAP KINASE SIGNALING SYSTEM; MELANOMA; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 58149340657     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1002     Document Type: Article

References (29)

1. Fecher LA, Cummings SD, Keefe MJ, Alani RM. Toward a molecular classification of melanoma. J Clin Oncol 2007;25:1606-20.
2. Kalinsky K, Haluska FG. Novel inhibitors in the treatment of metastatic melanoma. Expert Rev Anticancer Ther 2007;7:715-24.
3. Johansson P, Pavey S, Hayward N. Confirmation of a BRAF mutation-associated gene expression signature in melanoma. PigmentCell Res2007;20:216-21.
4. Goel VK, Lazar AJ, Warneke CL, Redston MS, Haluska FG. Examination of mutations in BRAF, NRAS, PTEN in primary cutaneous melanoma. J Invest Dermatol 2006;126:154-60.
5. Stebbins CE, RussoAA, Schneider C, Rosen N, Hartl FU, Pavletich NP. Crystal structure of an Hsp90-gel- danamycin complex: targeting of a protein chaperone by an antitumor agent. Cell 1997;89:239-50.
6. SchulteTW, Blagosklonny MV, Romanova L, et al. Destabilization of Raf-1 by geldanamycin leads to disruption of the Raf-1-MEK-mitogen-activated protein kinase signalling pathway. Mol Cell Biol 1996;16: 5839-45.
7. Stancato LF, Silverstein AM, Owens-Grillo JK, Chow YH, Jove R, Pratt WB. The hsp90-binding antibiotic geldanamycin decreases Raf levels and epidermal growth factor signaling without disrupting formation of signaling complexes or reducing the specific enzymatic activity of Raf kinase. J Biol Chem 1997;272: 4013-20.
8. Grbovic OM, Basso AD, Sawai A, et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci U S A2006;103:57-62.
9. Sato S, Fujita N,TsuruoT. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci U S A2000;97:10832-7.
10. Stepanova L, Leng X, Parker SB, Harper JW. Mam- malianp50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 1996;10:1491 -502.
11. 11.MunsterPN,Srethapakdi M,MoasserMM,Rosen N. Inhibition of heat shock protein 90 function by ansa- mycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res 2001; 61:2945-52.
12. Grem JL, Morrison G, Guo XD, et al. Phase I and pharmacologic study of 17-(allylamino)-17-demethox- ygeldanamycin in adult patients with solid tumors. J Clin Oncol 2005;23:1885-93.
13. Ramanathan RK, Egorin MJ, Eiseman JL, et al. Phase I and pharmacodynamic study of 17-(allyla- mino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 2007;13:1769-74.
14. Solit DB, Ivy SP, Kopil C, et al. Phase I trial of17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer 10.1158/1078-0432.CCR-06- 1863. Clin Cancer Res 2007;13:1775-82.
15. Banerji U, O'Donnell A, Scurr M, et al. Phase I phar- macokinetic and pharmacodynamic studyof17-allyla- mino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005;23: 4152-61.
16. Goetz MP, Toft D, Reid J, et al. Phase I trial of 17-allylamino-17- demethoxygeldanamycin in patients with advanced cancer. J Clin Oncol 2005;23: 1078-87.
17. Gorden A, Osman I, Gai W, et al. Analysis of BRAF and N-RAS mutations in metastatic melanoma tissues. Cancer Res 2003;63:3955 -7.
18. YancovitzM,YoonJ,MikhailM,etal.Detection of mutant BRAF alleles in the plasma of patients with metastatic melanoma. J Mol Diagn 2007;9: 178-83.
19. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417: 949-54.
20. Bagatell R, Gore L, Egorin MJ, et al. Phase I phar- macokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a Pediatric Oncology Experimental Therapeutics Investi-gators Consortium study 10.1158/1078-0432.CCR- 06-1892. Clin Cancer Res2007;13:1783-8.
21. Weigel BJ, Blaney SM, Reid JM, et al. A phase I study of 17-allylaminogeldanamycin in relapsed/ refractory pediatric patients with solid tumors: a Children's Oncology Group Study 10.1158/1078-0432.CCR-06-2270. Clin Cancer Res 2007;13: 1789-93.
22. UrbanT, Ricci S, Grange J-D, et al. Detection of c-Ki-ras mutation by PCR-RFLP analysis and diagnosis of pancreatic adenocarcinoma. J Natl Cancer Inst 1993;85:2008-12.
23. de Kok JB, van SolingeWW, RuersTJ, et al. Detection of tumour DNA in serum of colorectal cancer patients. ScandJClin Lab Invest 1997;57:601-4.
24. Kopreski MS,Benko FA, KweeC, et al. Detection of mutantK-rasDNA in plasma or serum of patients with colorectal cancer. BrJCancer1997;76:1293-9.
25. YamadaT, Nakamori S, Ohzato H, et al. Detection of K-ras gene mutations in plasma DNA of patients with pancreatic adenocarcinoma: correlation with clinicopathological features. Clin Cancer Res 1998;4: 1527-32.
26. Heath EI, Hillman D,Vaishampayan U, et al. Aphase II trial of 17-allylamino-17-demethoxygeldanamycin (17-AAG) in patients with hormone-refractory meta- static prostate cancer. J Clin Oncol Meet Abstracts 2007;25:15553.
27. Ronnen E A, Kondagunta GV, Ishill N, et al. A phase II trial of 17-(allylamino)-17-demethoxygeldanamycin in patients with papillary and clear cell renal cell carcinoma. Invest New Drugs 2006;24:543-6.
28. Basso AD, Solit DB, Munster PN, Rosen N. Ansa-mycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene2002;21:1159-66.
29. Modi S,Stopeck AT,GordonMS,etal.Thecombination of trastuzumab and tanespimycin (KOS 953,17-AAG) is safe and active in trastuzumab-refractory HER2 overexpressing breast cancer: a phase1 dose-escalationstudy. J Clin Oncol 2007;25:5410-7.